215 related articles for article (PubMed ID: 12240934)
1. Insoluble powder formulation as an effective nasal drug delivery system.
Ishikawa F; Murano M; Hiraishi M; Yamaguchi T; Tamai I; Tsuji A
Pharm Res; 2002 Aug; 19(8):1097-104. PubMed ID: 12240934
[TBL] [Abstract][Full Text] [Related]
2. Improved nasal bioavailability of elcatonin by insoluble powder formulation.
Ishikawa F; Katsura M; Tamai I; Tsuji A
Int J Pharm; 2001 Aug; 224(1-2):105-14. PubMed ID: 11472819
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the Absorption of Nanosized lamotrigine Containing Nasal Powder via the Nasal Cavity.
Ambrus R; Gieszinger P; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Janáky T; Tömösi F; Kecskeméti G; Szabó-Révész P; Bartos C
Molecules; 2020 Feb; 25(5):. PubMed ID: 32120992
[TBL] [Abstract][Full Text] [Related]
4. Dry powder nasal vaccines as an alternative to needle-based delivery.
Hickey AJ; Garmise RJ
Crit Rev Ther Drug Carrier Syst; 2009; 26(1):1-27. PubMed ID: 19496746
[TBL] [Abstract][Full Text] [Related]
5. Nasal drug absorption from powder formulations: The effect of three types of hydroxypropyl cellulose (HPC).
Tanaka A; Furubayashi T; Tomisaki M; Kawakami M; Kimura S; Inoue D; Kusamori K; Katsumi H; Sakane T; Yamamoto A
Eur J Pharm Sci; 2017 Jan; 96():284-289. PubMed ID: 27664332
[TBL] [Abstract][Full Text] [Related]
6. The Enhancement of Nasal Drug Absorption From Powder Formulations by the Addition of Sodium Carboxymethyl Cellulose.
Tanaka A; Furubayashi T; Yamasaki H; Takano K; Kawakami M; Kimura S; Inoue D; Katsumi H; Sakane T; Yamamoto A
IEEE Trans Nanobioscience; 2016 Dec; 15(8):798-803. PubMed ID: 28060709
[TBL] [Abstract][Full Text] [Related]
7. Effect of poly-L-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats.
Miyamoto M; Natsume H; Satoh I; Ohtake K; Yamaguchi M; Kobayashi D; Sugibayashi K; Morimoto Y
Int J Pharm; 2001 Sep; 226(1-2):127-38. PubMed ID: 11532576
[TBL] [Abstract][Full Text] [Related]
8. [Optimization of Nasal Drug Absorption from Powder Formulations: The Feasibility of Controlling Drug Absorption by the Use of Pharmaceutical Excipients].
Tanaka A
Yakugaku Zasshi; 2018; 138(12):1467-1472. PubMed ID: 30504659
[TBL] [Abstract][Full Text] [Related]
9. Nasal Absorption of Macromolecules from Powder Formulations and Effects of Sodium Carboxymethyl Cellulose on Their Absorption.
Tanaka A; Furubayashi T; Matsushita A; Inoue D; Kimura S; Katsumi H; Sakane T; Yamamoto A
PLoS One; 2016; 11(9):e0159150. PubMed ID: 27598527
[TBL] [Abstract][Full Text] [Related]
10. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs.
Gonçalves VSS; Matias AA; Poejo J; Serra AT; Duarte CMM
Int J Pharm; 2016 Dec; 515(1-2):1-10. PubMed ID: 27702697
[TBL] [Abstract][Full Text] [Related]
11. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
[TBL] [Abstract][Full Text] [Related]
12. Nasal delivery of insulin using novel chitosan based formulations: a comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles.
Dyer AM; Hinchcliffe M; Watts P; Castile J; Jabbal-Gill I; Nankervis R; Smith A; Illum L
Pharm Res; 2002 Jul; 19(7):998-1008. PubMed ID: 12180553
[TBL] [Abstract][Full Text] [Related]
13. Influence of formulation viscosity on drug absorption following nasal application in rats.
Furubayashi T; Inoue D; Kamaguchi A; Higashi Y; Sakane T
Drug Metab Pharmacokinet; 2007 Jun; 22(3):206-11. PubMed ID: 17603222
[TBL] [Abstract][Full Text] [Related]
14. Nasal Drug Absorption from Powder Formulations: Effect of Fluid Volume Changes on the Mucosal Surface.
Tanaka A; Furubayashi T; Enomura Y; Hori T; Shimomura R; Maeda C; Kimura S; Inoue D; Kusamori K; Katsumi H; Sakane T; Yamamoto A
Biol Pharm Bull; 2017; 40(2):212-219. PubMed ID: 28154262
[TBL] [Abstract][Full Text] [Related]
15. Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery.
Pozzoli M; Traini D; Young PM; Sukkar MB; Sonvico F
Drug Dev Ind Pharm; 2017 Sep; 43(9):1510-1518. PubMed ID: 28425305
[TBL] [Abstract][Full Text] [Related]
16. Influence of deposition and spray pattern of nasal powders on insulin bioavailability.
Pringels E; Callens C; Vervaet C; Dumont F; Slegers G; Foreman P; Remon JP
Int J Pharm; 2006 Mar; 310(1-2):1-7. PubMed ID: 16427222
[TBL] [Abstract][Full Text] [Related]
17. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device.
Luthringer R; Djupesland PG; Sheldrake CD; Flint A; Boeijinga P; Danjou P; Demazières A; Hewson G
J Pharm Pharmacol; 2009 Sep; 61(9):1219-28. PubMed ID: 19703372
[TBL] [Abstract][Full Text] [Related]
18. Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats.
Balducci AG; Ferraro L; Bortolotti F; Nastruzzi C; Colombo P; Sonvico F; Russo P; Colombo G
Int J Pharm; 2013 Jan; 440(2):154-60. PubMed ID: 23046665
[TBL] [Abstract][Full Text] [Related]
19. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue.
Horvát S; Fehér A; Wolburg H; Sipos P; Veszelka S; Tóth A; Kis L; Kurunczi A; Balogh G; Kürti L; Eros I; Szabó-Révész P; Deli MA
Eur J Pharm Biopharm; 2009 May; 72(1):252-9. PubMed ID: 19007885
[TBL] [Abstract][Full Text] [Related]
20. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump.
Djupesland PG; Skretting A
J Aerosol Med Pulm Drug Deliv; 2012 Oct; 25(5):280-9. PubMed ID: 22251061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
